Matches in SemOpenAlex for { <https://semopenalex.org/work/W2001373275> ?p ?o ?g. }
Showing items 1 to 81 of
81
with 100 items per page.
- W2001373275 endingPage "741" @default.
- W2001373275 startingPage "732" @default.
- W2001373275 abstract "Background: Botulinum toxin type A has been widely used to correct unwanted hyperfunctional facial lines. Most forms of botulinum toxin type A currently used require reconstitution, which is very inconvenient for users. The authors compared the efficacy and safety of a newly developed liquid-type botulinum toxin type A (MT10109L) and onabotulinumtoxinA (Botox) for moderate to severe glabellar lines. Methods: A double-blind, randomized, active drug–controlled, phase III study with 168 enrolled subjects was performed. The primary efficacy endpoint was the improvement rate at maximum frown at week 4 by the investigators’ live assessment. The secondary efficacy endpoint included the improvement rate at maximum frown at week 16 and at rest at weeks 4 and 16 by live assessment, and the improvement rate at maximum frown and at rest based on photographic assessment at week 4. Self-assessment and self-satisfaction with glabellar line improvement were also evaluated. Results: The improvement rate at maximum frown by live assessment was not significantly different between the MT10109L and Botox groups. In addition, the improvement rate of glabellar lines at rest based on the investigators’ live assessment and photographic assessment was similar in both treatment groups. However, the improvement rate at maximum frown by live assessment at week 16 was significantly higher in the MT10109L group compared with the Botox group. There were no severe adverse events. Conclusions: The efficacy and safety of MT10109L were comparable to those of Botox for the management of glabellar frown lines. MT10109L provides greater convenience because it does not require dilution and has long-lasting effects. CLINICAL QUESTION/LEVEL OF EVIDENCE: Therapeutic, II." @default.
- W2001373275 created "2016-06-24" @default.
- W2001373275 creator A5002056660 @default.
- W2001373275 creator A5021341806 @default.
- W2001373275 creator A5063556691 @default.
- W2001373275 creator A5066898513 @default.
- W2001373275 creator A5080810020 @default.
- W2001373275 creator A5082907572 @default.
- W2001373275 date "2015-03-01" @default.
- W2001373275 modified "2023-09-26" @default.
- W2001373275 title "The Efficacy and Safety of Liquid-Type Botulinum Toxin Type A for the Management of Moderate to Severe Glabellar Frown Lines" @default.
- W2001373275 cites W1965142158 @default.
- W2001373275 cites W1970066703 @default.
- W2001373275 cites W1975308015 @default.
- W2001373275 cites W1978910356 @default.
- W2001373275 cites W1993554276 @default.
- W2001373275 cites W2007032993 @default.
- W2001373275 cites W2011283002 @default.
- W2001373275 cites W2033132384 @default.
- W2001373275 cites W2072504962 @default.
- W2001373275 cites W2101169964 @default.
- W2001373275 cites W4226153170 @default.
- W2001373275 cites W4360754078 @default.
- W2001373275 cites W4363610867 @default.
- W2001373275 doi "https://doi.org/10.1097/prs.0000000000001032" @default.
- W2001373275 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25719692" @default.
- W2001373275 hasPublicationYear "2015" @default.
- W2001373275 type Work @default.
- W2001373275 sameAs 2001373275 @default.
- W2001373275 citedByCount "16" @default.
- W2001373275 countsByYear W20013732752016 @default.
- W2001373275 countsByYear W20013732752017 @default.
- W2001373275 countsByYear W20013732752019 @default.
- W2001373275 countsByYear W20013732752020 @default.
- W2001373275 countsByYear W20013732752021 @default.
- W2001373275 countsByYear W20013732752022 @default.
- W2001373275 countsByYear W20013732752023 @default.
- W2001373275 crossrefType "journal-article" @default.
- W2001373275 hasAuthorship W2001373275A5002056660 @default.
- W2001373275 hasAuthorship W2001373275A5021341806 @default.
- W2001373275 hasAuthorship W2001373275A5063556691 @default.
- W2001373275 hasAuthorship W2001373275A5066898513 @default.
- W2001373275 hasAuthorship W2001373275A5080810020 @default.
- W2001373275 hasAuthorship W2001373275A5082907572 @default.
- W2001373275 hasConcept C126322002 @default.
- W2001373275 hasConcept C141071460 @default.
- W2001373275 hasConcept C168563851 @default.
- W2001373275 hasConcept C197934379 @default.
- W2001373275 hasConcept C203092338 @default.
- W2001373275 hasConcept C2777478456 @default.
- W2001373275 hasConcept C2780446394 @default.
- W2001373275 hasConcept C71924100 @default.
- W2001373275 hasConceptScore W2001373275C126322002 @default.
- W2001373275 hasConceptScore W2001373275C141071460 @default.
- W2001373275 hasConceptScore W2001373275C168563851 @default.
- W2001373275 hasConceptScore W2001373275C197934379 @default.
- W2001373275 hasConceptScore W2001373275C203092338 @default.
- W2001373275 hasConceptScore W2001373275C2777478456 @default.
- W2001373275 hasConceptScore W2001373275C2780446394 @default.
- W2001373275 hasConceptScore W2001373275C71924100 @default.
- W2001373275 hasIssue "3" @default.
- W2001373275 hasLocation W20013732751 @default.
- W2001373275 hasOpenAccess W2001373275 @default.
- W2001373275 hasPrimaryLocation W20013732751 @default.
- W2001373275 hasRelatedWork W2003938723 @default.
- W2001373275 hasRelatedWork W2047967234 @default.
- W2001373275 hasRelatedWork W2118496982 @default.
- W2001373275 hasRelatedWork W2364998975 @default.
- W2001373275 hasRelatedWork W2378634459 @default.
- W2001373275 hasRelatedWork W2439875401 @default.
- W2001373275 hasRelatedWork W3167894203 @default.
- W2001373275 hasRelatedWork W3212257619 @default.
- W2001373275 hasRelatedWork W4238867864 @default.
- W2001373275 hasRelatedWork W2525756941 @default.
- W2001373275 hasVolume "135" @default.
- W2001373275 isParatext "false" @default.
- W2001373275 isRetracted "false" @default.
- W2001373275 magId "2001373275" @default.
- W2001373275 workType "article" @default.